Cancer Policy COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC July 25, 2025Vol.51 No.29By Paul Goldberg
Funding Opportunities FDA OCE issues RFA for cooperative agreements for evaluation of cardiotoxicity July 25, 2025Vol.51 No.29
Drugs & Targets FDA extends review period for Blenrep combinations after unfavorable ODAC vote, EU approval July 25, 2025Vol.51 No.29By Jacquelyn Cobb
Drugs & Targets FDA issues CRL for RP1+ nivolumab BLA for treatment of advanced melanoma July 25, 2025Vol.51 No.29
Drugs & Targets FDA grants Breakthrough Therapy designation to elironrasib for lung cancer July 25, 2025Vol.51 No.29
Regulatory News ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population July 18, 2025Vol.51 No.28By Jacquelyn Cobb and Sara Willa Ernst
Sponsored Imaging’s ride to the bottom in clinical trials—and why it matters now July 18, 2025Vol.51 No.28By Jeff Sorenson
Cancer Policy NIH says it’s moving away from animal-based models July 18, 2025Vol.51 No.28By Claire Marie Porter
Drugs & Targets FDA gives TAR-200 Priority Review for invasive bladder cancer July 18, 2025Vol.51 No.28
FreeIn the Archives Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology July 11, 2025Vol.51 No.27By Katie Goldberg
